NewAmsterdam Total Assets from 2010 to 2026

NAMSW Stock

25.97 2.79 12.04%

NewAmsterdam Pharma Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 489 M in 2026. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2020-03-31

Previous Quarter

786.4 M

Current Value

769.3 M

Quarterly Volatility

295.6 M

Covid

Interest Hikes

Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 29 M or Interest Income of 29 M, as well as many indicators such as Price To Sales Ratio of 187, Dividend Yield of 0.0 or PTB Ratio of 6.17. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.

Build AI portfolio with NewAmsterdam Stock

Check out the analysis of NewAmsterdam Pharma Correlation against competitors.

For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

The evolution of Total Assets for NewAmsterdam Pharma provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how NewAmsterdam Pharma compares to historical norms and industry peers.

Latest NewAmsterdam Pharma's Total Assets Growth Pattern

Below is the plot of the Total Assets of NewAmsterdam Pharma over the last few years. Total assets refers to the total amount of NewAmsterdam Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in NewAmsterdam Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. NewAmsterdam Pharma's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 769.28 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

NewAmsterdam Total Assets Regression Statistics

	Arithmetic Mean	267,945,136
	Geometric Mean	201,371,209
	Coefficient Of Variation	89.84
	Mean Deviation	189,269,124
	Median	139,869,628
	Standard Deviation	240,734,569
	Sample Variance	57953.1T
	Range	796.6M
	R-Value	0.71
	Mean Square Error	31047.2T
	R-Squared	0.50
	Significance	0
	Slope	33,633,749
	Total Sum of Squares	927250.1T

NewAmsterdam Total Assets History

	2026	489 M
	2025	769.3 M
	2024	864.6 M
	2023	347.1 M
	2022	478.5 M
	2021	68 M

Other Fundumenentals of NewAmsterdam Pharma

Intangibles To Total Assets

NewAmsterdam Pharma Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Current Deferred Revenue	Net Receivables	Good Will	Intangible Assets
Total Assets		1.0	-0.96	-0.89	0.57	0.98	0.93	-0.46	0.98	0.22	0.93	-0.74	-0.71	0.46	0.84	-0.46	0.88
Total Stockholder Equity	1.0		-0.95	-0.89	0.55	0.98	0.93	-0.46	0.98	0.23	0.92	-0.73	-0.7	0.45	0.84	-0.46	0.88
Net Debt	-0.96	-0.95		0.88	-0.7	-0.97	-0.94	0.49	-0.99	-0.33	-0.93	0.85	0.83	-0.61	-0.7	0.49	-0.81
Retained Earnings	-0.89	-0.89	0.88		-0.63	-0.9	-0.97	0.77	-0.88	0.0	-0.98	0.77	0.73	-0.29	-0.82	0.77	-0.82
Accounts Payable	0.57	0.55	-0.7	-0.63		0.65	0.65	-0.37	0.67	0.45	0.65	-0.9	-0.89	0.77	0.18	-0.37	0.22
Total Liab	0.98	0.98	-0.97	-0.9	0.65		0.92	-0.45	0.99	0.16	0.92	-0.8	-0.77	0.48	0.8	-0.45	0.85
Net Invested Capital	0.93	0.93	-0.94	-0.97	0.65	0.92		-0.74	0.93	0.23	1.0	-0.81	-0.77	0.45	0.77	-0.74	0.82
Short Long Term Debt	-0.46	-0.46	0.49	0.77	-0.37	-0.45	-0.74		-0.45	0.08	-0.75	0.46	0.41	-0.05	-0.5	1.0	-0.49
Total Current Assets	0.98	0.98	-0.99	-0.88	0.67	0.99	0.93	-0.45		0.3	0.93	-0.83	-0.81	0.55	0.77	-0.45	0.84
Capital Stock	0.22	0.23	-0.33	0.0	0.45	0.16	0.23	0.08	0.3		0.18	-0.41	-0.42	0.83	-0.2	0.08	-0.09
Net Working Capital	0.93	0.92	-0.93	-0.98	0.65	0.92	1.0	-0.75	0.93	0.18		-0.81	-0.77	0.42	0.79	-0.75	0.83
Short Term Debt	-0.74	-0.73	0.85	0.77	-0.9	-0.8	-0.81	0.46	-0.83	-0.41	-0.81		1.0	-0.63	-0.48	0.46	-0.54
Common Stock	-0.71	-0.7	0.83	0.73	-0.89	-0.77	-0.77	0.41	-0.81	-0.42	-0.77	1.0		-0.63	-0.45	0.41	-0.51
Current Deferred Revenue	0.46	0.45	-0.61	-0.29	0.77	0.48	0.45	-0.05	0.55	0.83	0.42	-0.63	-0.63		-0.09	-0.05	0.06
Net Receivables	0.84	0.84	-0.7	-0.82	0.18	0.8	0.77	-0.5	0.77	-0.2	0.79	-0.48	-0.45	-0.09		-0.5	0.94
Good Will	-0.46	-0.46	0.49	0.77	-0.37	-0.45	-0.74	1.0	-0.45	0.08	-0.75	0.46	0.41	-0.05	-0.5		-0.49
Intangible Assets	0.88	0.88	-0.81	-0.82	0.22	0.85	0.82	-0.49	0.84	-0.09	0.83	-0.54	-0.51	0.06	0.94	-0.49

Click cells to compare fundamentals

About NewAmsterdam Pharma Financial Statements

NewAmsterdam Pharma investors use historical fundamental indicators, such as NewAmsterdam Pharma's Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NewAmsterdam Pharma. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	769.3 M	489 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

FSLY	Fastly Class A
MOB	Mobilicom Limited American
CMG	Chipotle Mexican Grill

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC